Advocacy Wealth Management Services LLC Decreases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Advocacy Wealth Management Services LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 32.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 204 shares of the company’s stock after selling 96 shares during the period. Advocacy Wealth Management Services LLC’s holdings in Johnson & Johnson were worth $29,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Altshuler Shaham Ltd purchased a new stake in Johnson & Johnson during the first quarter valued at approximately $35,000. Lake Point Wealth Management increased its holdings in Johnson & Johnson by 144.4% during the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after buying an additional 169 shares during the last quarter. Lion Street Advisors LLC purchased a new stake in Johnson & Johnson during the first quarter valued at approximately $45,000. Joseph P. Lucia & Associates LLC increased its holdings in Johnson & Johnson by 50.8% during the first quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock valued at $49,000 after buying an additional 126 shares during the last quarter. Finally, Permanens Capital L.P. increased its holdings in Johnson & Johnson by 100.0% during the first quarter. Permanens Capital L.P. now owns 400 shares of the company’s stock valued at $52,000 after buying an additional 200 shares during the last quarter. 68.51% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:JNJ traded up $0.70 during midday trading on Thursday, reaching $141.08. 300,156 shares of the company were exchanged, compared to its average volume of 8,091,820. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. The business’s fifty day moving average is $145.03 and its two-hundred day moving average is $143.98. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The stock has a market cap of $370.50 billion, a PE ratio of 18.57, a price-to-earnings-growth ratio of 3.07 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The firm had revenue of $20.69 billion during the quarter, compared to analyst estimates of $19.48 billion. During the same quarter in the prior year, the business earned $2.10 earnings per share. Johnson & Johnson’s revenue for the quarter was up 3.3% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 7.68 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were given a dividend of $1.01 per share. The ex-dividend date was Friday, May 22nd. This represents a $4.04 annualized dividend and a yield of 2.86%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.

A number of brokerages have recently issued reports on JNJ. Citigroup increased their price objective on shares of Johnson & Johnson from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $140.00 to $155.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. SVB Leerink reduced their price objective on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Argus reissued a “buy” rating and issued a $155.00 price objective (down from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. Finally, Wells Fargo & Co raised shares of Johnson & Johnson to a “hold” rating in a research note on Wednesday, April 22nd. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $163.47.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Accumulation/Distribution

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.